Polyrizon (PLRZ) Total Non-Current Liabilities (2025)

Polyrizon's (PLRZ) quarterly Total Non-Current Liabilities came in at $18.7 million in Q2 2025.

Polyrizon (PLRZ) Total Non-Current Liabilities (2025) Analysis & Trends

Polyrizon (PLRZ) has 1 years of Total Non-Current Liabilities data on file, last reported at $18.7 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.92 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	7.74 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	40.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	3.92 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.88 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	4.20 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	724.15 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.17 Bn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.32 Bn
10	Polyrizon	7.27 Mn	-4.22 Mn	-	-

Download Data

Date	Value
Jun 30, 2025	18.67 Mn